CSIMarket
 
Madrigal Pharmaceuticals Inc   (MDGL)
Other Ticker:  
 
 
Price: $270.3700 $26.80 11.003%
Day's High: $299.98 Week Perf: 3.93 %
Day's Low: $ 262.00 30 Day Perf: 24.03 %
Volume (M): 2,769 52 Wk High: $ 322.67
Volume (M$): $ 748,736 52 Wk Avg: $216.44
Open: $293.90 52 Wk Low: $119.76



 Market Capitalization (Millions $) 5,053
 Shares Outstanding (Millions) 19
 Employees 36
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -374
 Cash Flow (TTM) (Millions $) -232
 Capital Exp. (TTM) (Millions $) 1

Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that is focused on developing innovative therapies for the treatment of serious diseases that are impacting the lives of patients around the world. The company was founded in 2011 with the goal of using its expertise in the field of liver metabolism to develop novel drugs that can help patients with various forms of liver and cardiovascular diseases.

The company's flagship product is MGL-3196, which is a selective thyroid hormone receptor beta agonist that is designed to help patients suffering from non-alcoholic steatohepatitis (NASH), a serious liver disease that is characterized by inflammation and the accumulation of fat in the liver. The drug has shown significant promise in early clinical trials, and it is currently being evaluated in phase 3 clinical trials for the treatment of NASH.

Madrigal is also developing other products that are designed to address other liver and cardiovascular diseases. One of the company's other products is MGL-3745, which is a selective thyroid hormone receptor beta agonist that is designed to help patients suffering from dyslipidemia. Dyslipidemia is a condition that is characterized by high levels of cholesterol and triglycerides in the blood, which can lead to serious health problems such as heart disease and stroke.

In addition to its drug development efforts, Madrigal is also actively engaged in research and development activities aimed at discovering new and innovative therapies for other serious diseases. The company has a team of experienced researchers and scientists who are working to identify new drug targets and develop new drug candidates that can help patients suffering from a range of diseases.

Overall, Madrigal Pharmaceuticals Inc. is a highly innovative and promising biopharmaceutical company that is focused on developing new and effective treatments for serious diseases. With its focus on liver and cardiovascular diseases and its highly experienced team of researchers and scientists, the company is well-positioned to make a significant impact on the lives of patients around the world.


   Company Address: Four Tower Bridge West Conshohocken 19428 PA
   Company Phone Number: 824-2827   Stock Exchange / Ticker: NASDAQ MDGL
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Financing Agreement

Madrigal Pharmaceuticals Announces Proposed Public Offering to Accelerate Innovation in NASH Therapeutics

Published Mon, Mar 18 2024 8:04 PM UTC


Madrigal Pharmaceuticals Embarks on $500 Million Public Offering to Fuel Innovation in NASH Therapeutics
CONSHOHOCKEN, Pa., March 18, 2024 - Madrigal Pharmaceuticals, a leading biopharmaceutical company focused on groundbreaking treatments for nonalcoholic steatohepatitis (NASH), has recently unveiled its plans to undertake a substantial public offering of $500 mil...

Product Service News

Resmetirom Receives FDA Approval for the Treatment of Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

Published Thu, Mar 14 2024 8:15 PM UTC

Nonalcoholic steatohepatitis (NASH) is a progressive liver disease characterized by inflammation and fat accumulation in the liver, leading to liver fibrosis and potentially cirrhosis. The absence of effective pharmacological treatment options for NASH has fueled substantial research in the field. One notable breakthrough comes from Madrigal Pharmaceuticals as they announce ...

Shares

Madrigal Pharmaceuticals Announces Inducement Grants, Bolstering Company's Growth Prospects

Published Wed, Mar 6 2024 9:05 PM UTC



Madrigal Pharmaceuticals, a renowned clinical-stage biopharmaceutical company focusing on innovative treatments for nonalcoholic steatohepatitis (NASH), made a significant announcement today regarding equity awards granted to key personnel. The company's latest move reflects strategic efforts to strengthen its leadership team and expand its operations. With this up...

Product Service News

Resmetirom Boosts NASH/MASH Treatment: A Promising Breakthrough for Liver Fibrosis

Published Tue, Mar 5 2024 1:01 PM UTC

Nonalcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis have become significant global health concerns. With limited available treatment options, patients suffering from these conditions face a high risk of developing severe liver-related complications. However, recent advancements in pharmaceutical research have sp...

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc Faces Decline in Shares, Operating Loss in Fourth Quarter of 2023

Madrigal Pharmaceuticals Inc, a clinical-stage biopharmaceutical company focused on developing therapeutics for nonalcoholic steatohepatitis (NASH), has experienced a decline in its shares in February 2024. The shares dropped by 6.44% so far this month, and by 14.36% compared to the same period last year. Despite this, Madrigal Pharmaceuticals Inc shares are currently trading on the NASDAQ at 9.1% above its 52-week average.
In the recent months, shareholders did not anticipate any changes to the company's top-line revenue during the October to December 2023 reporting cycle. However, they closely monitored the operating loss of Madrigal Pharmaceuticals Inc, which amounted to $-117.176 million during the same period. It is worth noting that the company has not yet declared its revenue, but to better understand its recent efforts, we can compare it to the operating loss of $-85.299 million in the fourth quarter of 2022.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com